616 related articles for article (PubMed ID: 23847203)
21. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
[TBL] [Abstract][Full Text] [Related]
22. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.
Jiang JX; Sun CY; Tian S; Yu C; Chen MY; Zhang H
Tumour Biol; 2016 Oct; 37(10):13893-13902. PubMed ID: 27485116
[TBL] [Abstract][Full Text] [Related]
23. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner.
Hao HX; Xie Y; Zhang Y; Charlat O; Oster E; Avello M; Lei H; Mickanin C; Liu D; Ruffner H; Mao X; Ma Q; Zamponi R; Bouwmeester T; Finan PM; Kirschner MW; Porter JA; Serluca FC; Cong F
Nature; 2012 Apr; 485(7397):195-200. PubMed ID: 22575959
[TBL] [Abstract][Full Text] [Related]
24. WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.
Arensman MD; Kovochich AN; Kulikauskas RM; Lay AR; Yang PT; Li X; Donahue T; Major MB; Moon RT; Chien AJ; Dawson DW
Oncogene; 2014 Feb; 33(7):899-908. PubMed ID: 23416978
[TBL] [Abstract][Full Text] [Related]
25. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
[TBL] [Abstract][Full Text] [Related]
26. Protease associated domain of RNF43 is not necessary for the suppression of Wnt/β-catenin signaling in human cells.
Radaszkiewicz T; Bryja V
Cell Commun Signal; 2020 Jun; 18(1):91. PubMed ID: 32527265
[TBL] [Abstract][Full Text] [Related]
27. The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis.
Tu J; Park S; Yu W; Zhang S; Wu L; Carmon K; Liu QJ
Sci Rep; 2019 Dec; 9(1):18557. PubMed ID: 31811196
[TBL] [Abstract][Full Text] [Related]
28. Coupling G2/M arrest to the Wnt/β-catenin pathway restrains pancreatic adenocarcinoma.
Sarkar S; Mandal C; Sangwan R; Mandal C
Endocr Relat Cancer; 2014 Feb; 21(1):113-25. PubMed ID: 24402132
[TBL] [Abstract][Full Text] [Related]
29. Cell biology. The unusual case of Porcupine.
Lum L; Clevers H
Science; 2012 Aug; 337(6097):922-3. PubMed ID: 22923569
[TBL] [Abstract][Full Text] [Related]
30. The structural basis of R-spondin recognition by LGR5 and RNF43.
Chen PH; Chen X; Lin Z; Fang D; He X
Genes Dev; 2013 Jun; 27(12):1345-50. PubMed ID: 23756651
[TBL] [Abstract][Full Text] [Related]
31. RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer.
Spit M; Fenderico N; Jordens I; Radaszkiewicz T; Lindeboom RG; Bugter JM; Cristobal A; Ootes L; van Osch M; Janssen E; Boonekamp KE; Hanakova K; Potesil D; Zdrahal Z; Boj SF; Medema JP; Bryja V; Koo BK; Vermeulen M; Maurice MM
EMBO J; 2020 Sep; 39(18):e103932. PubMed ID: 32965059
[TBL] [Abstract][Full Text] [Related]
32. DDB2 Is a Novel Regulator of Wnt Signaling in Colon Cancer.
Huang S; Fantini D; Merrill BJ; Bagchi S; Guzman G; Raychaudhuri P
Cancer Res; 2017 Dec; 77(23):6562-6575. PubMed ID: 29021137
[TBL] [Abstract][Full Text] [Related]
33. Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor RNF43 in early gastric carcinogenesis.
Min BH; Hwang J; Kim NK; Park G; Kang SY; Ahn S; Ahn S; Ha SY; Lee YK; Kushima R; Van Vrancken M; Kim MJ; Park C; Park HY; Chae J; Jang SS; Kim SJ; Kim YH; Kim JI; Kim KM
J Pathol; 2016 Nov; 240(3):304-314. PubMed ID: 27514024
[TBL] [Abstract][Full Text] [Related]
34. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
[TBL] [Abstract][Full Text] [Related]
35. Activation of WNT/β-Catenin Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via Up-regulation of Cyr61.
Sano M; Driscoll DR; DeJesus-Monge WE; Quattrochi B; Appleman VA; Ou J; Zhu LJ; Yoshida N; Yamazaki S; Takayama T; Sugitani M; Nemoto N; Klimstra DS; Lewis BC
Neoplasia; 2016 Dec; 18(12):785-794. PubMed ID: 27889647
[TBL] [Abstract][Full Text] [Related]
36. RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells.
Hsu SH; Tsai YL; Wang YT; Shen CH; Hung YH; Chen LT; Hung WC
Adv Sci (Weinh); 2024 Mar; 11(12):e2304820. PubMed ID: 38225722
[TBL] [Abstract][Full Text] [Related]
37. A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties.
Pavlovic Z; Adams JJ; Blazer LL; Gakhal AK; Jarvik N; Steinhart Z; Robitaille M; Mascall K; Pan J; Angers S; Moffat J; Sidhu SS
MAbs; 2018; 10(8):1157-1167. PubMed ID: 30183492
[TBL] [Abstract][Full Text] [Related]
38. RNF43 ubiquitinates and degrades phosphorylated E-cadherin by c-Src to facilitate epithelial-mesenchymal transition in lung adenocarcinoma.
Zhang Y; Sun L; Gao X; Guo A; Diao Y; Zhao Y
BMC Cancer; 2019 Jul; 19(1):670. PubMed ID: 31286874
[TBL] [Abstract][Full Text] [Related]
39. Recurrent mutations in tumor suppressor
Zhong Z; Virshup DM
Sci Adv; 2024 Apr; 10(14):eadk1031. PubMed ID: 38569029
[TBL] [Abstract][Full Text] [Related]
40. Issues with RNF43 antibodies to reliably detect intracellular location.
Li S; Zhang R; Lavrijsen M; van den Bosch TPP; Peppelenbosch MP; Smits R
PLoS One; 2023; 18(4):e0283894. PubMed ID: 37023034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
